GlaxoSmithKline to ship 600,000 more doses of COVID treatment sotrovimab to U.S.Market Watch • 01/11/22
GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19GlobeNewsWire • 01/11/22
GlaxoSmithKline, Vir increases supply of COVID-19 antibody therapy to Canada to 20,000 dosesMarket Watch • 01/06/22
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor EngagementGlobeNewsWire • 12/31/21
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19GlobeNewsWire • 12/17/21
Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited AntibodiesGlobeNewsWire • 12/14/21
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus InfectionGlobeNewsWire • 12/09/21
Vir Biotechnology to Host a Call on Sotrovimab's Retained Activity Against the Omicron SARS-CoV-2 VariantGlobeNewsWire • 12/07/21
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 VariantGlobeNewsWire • 12/07/21
Vir Biotech - GSK's COVID-19 Antibody Shows Preclinical Activity Against Omicron VariantBenzinga • 12/02/21
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 VariantGlobeNewsWire • 12/02/21